Tags: Heart Disease | heart | failure | drug | LCZ696

'Blockbuster' Heart Failure Drug Expected Next Year

Tuesday, 28 October 2014 08:13 AM

Novartis expects its new heart failure drug to be a "multi-blockbuster" with sales between $2 billion and $5 billion, the company's chief executive said on Tuesday.
 
The Swiss drugmaker reported data for LCZ696 in August, which found the drug cut the risk of both cardiovascular death and admissions to hospital by a fifth.

Some analysts have suggested the medicine could notch up sales of $8-$10 billion, but Novartis Chief Executive Joe Jimenez said he thought those forecasts were a bit "too optimistic."
 
"Even though it's early, the data would support this drug being a multi-blockbuster. I've seen estimates of somewhere between $2 and $5 billion, and I think if you look at the data...I believe it should fall in that ballpark," he told reporters on a third-quarter results earning call.

"I think some of the analyst projections of between $8 and $10 billion are probably too optimistic, but again we don't know until we launch the brand and see the reaction."

Jimenez said Novartis was on track to submit the drug to U.S. health regulators by December and expects a decision by the Food and Drug Administration towards the end of 2015.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Novartis expects its new heart failure drug to be a multi-blockbuster with sales between $2 billion and $5 billion, the company's chief executive said on Tuesday. The Swiss drugmaker reported data for LCZ696 in August, which found the drug cut the risk of both cardiovascular...
heart, failure, drug, LCZ696
192
2014-13-28
Tuesday, 28 October 2014 08:13 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved